Core Viewpoint - The company has reclaimed global rights for IMM2510 (PD-L1/VEGF) and IMM27M (CTLA-4 ADCC+) from Instil Bio, indicating a strategic correction in its licensing approach. This decision allows the company to regain control over its development strategy and clinical progress [1]. Group 1 - The return of overseas rights for IMM2510 and IMM27M allows the company to seek new partnerships and regain full global rights, enhancing its strategic flexibility [1]. - Instil Bio's slow progress in the 15 months following the licensing agreement raised market concerns about its execution capabilities, making the company's decision to terminate the agreement a prudent move [1]. - The company now has the opportunity to re-establish its development strategy and clinical timelines for these assets [1]. Group 2 - The IMM27M (CTLA-4 ADCC+) asset has gained renewed attention due to its potential in combination therapies, especially following positive data from BioNTech/OncoC4's new CTLA-4 antibody, Gotistobart [2]. - The combination of VEGF/PD-L1 and CTLA-4 offers significant potential for future therapies, with CTLA-4 providing flexibility in dosing and administration, potentially reducing safety risks [2]. Group 3 - The company's core focus includes the CD47 pipeline, particularly IMM01 (sirpα-Fc fusion protein), which is advancing in Phase III clinical trials for chronic myelomonocytic leukemia (CMML) [3]. - IMM0306 (CD47/CD20), developed from IMM01, is gaining attention as one of the fastest progressing MCE molecules, with strategic value demonstrated by recent collaborations in the field [3]. Group 4 - In the autoimmune sector, IMM0306 has shown promising Phase Ib data for systemic lupus erythematosus, with response rates of 71.4% and 80.0% at different dosages, highlighting its convenience and efficacy [4]. - In oncology, Phase II data presented at the 2025 ASH meeting showed an overall response rate (ORR) of 91.2% and a complete response (CR) rate of 67.6% for relapsed refractory follicular lymphoma, with plans for a Phase III trial to start in Q1 2026 [4]. - The reclamation of key assets and the differentiated pipeline in oncology and autoimmune diseases position the company favorably for future clinical advancements and business development collaborations [4].

Group 1: Market Performance - The US stock market saw all three major indices rise, with the Dow Jones Industrial Average reaching a historic high, closing at 49,462.08 points, just shy of the 50,000 mark [3] - The Philadelphia Semiconductor Index increased by 2.75%, setting a new record, with notable gains in chip stocks such as Microchip Technology up over 11% and Micron Technology up over 10% [2][6] - Energy stocks mostly declined, with Chevron down over 4% and ExxonMobil down over 3% [7] Group 2: Federal Reserve Insights - Federal Reserve Governor Milan indicated that the Fed should lower interest rates by more than 100 basis points this year, citing a return to the 2% inflation target and strong economic growth [5] - Richmond Fed President Barkin mentioned that after a cumulative rate cut of 75 basis points by 2025, rates would enter a neutral range, necessitating a balance between full employment and inflation control [5] Group 3: Commodity Market Movements - Silver prices surged, with COMEX silver futures breaking the $80 per ounce mark, reflecting a rise of approximately 6% [10] - Gold prices also saw a slight increase, with COMEX gold futures surpassing $4,500 per ounce, marking a gain of over 1% [10] - NYMEX WTI crude oil futures fell below $57 per barrel, with a decline of over 2% [11]

Core Viewpoint - The company, Yiming Oncology, has reclaimed global rights for IMM2510 (PD-L1/VEGF) and IMM27M (CTLA-4 ADCC+) from Instil Bio, indicating a strategic correction in its licensing approach. This decision allows the company to regain control over its assets and explore new partnerships while managing its development strategy and clinical progress more effectively [1][4]. Group 1: Asset Reclamation - The company has retrieved global rights for IMM2510 and IMM27M, which were previously licensed to Instil Bio for a $50 million upfront payment and additional milestone payments totaling $2 billion. This move is seen as a timely decision to mitigate potential losses due to Instil's slow progress in development [1]. - Instil Bio's slow advancement, with the first patient enrollment in the U.S. not expected until November 2025, raised concerns about its execution capabilities [1]. Group 2: CTLA-4 and Combination Therapy Potential - The IMM27M asset, targeting CTLA-4, has gained renewed attention due to its potential in combination therapies, especially following positive data from BioNTech/OncoC4's new CTLA-4 antibody, Gotistobart. This highlights the significant future potential for combination therapies involving both VEGF/PD-L1 and CTLA-4 [2]. - CTLA-4 as a monoclonal antibody offers flexibility in dosing and administration frequency, which may help reduce safety risks associated with its use [2]. Group 3: CD47 Pipeline and Clinical Progress - The company's core focus includes the CD47 pipeline, particularly the lead product IMM01 (sirpα-Fc fusion protein), which is advancing in Phase III clinical trials for chronic myelomonocytic leukemia (CMML). A mid-term analysis is expected within the year, with promising efficacy and safety data accumulated so far [3]. - The IMM0306 molecule, based on IMM01, is one of the fastest-developing MCE molecules, indicating strategic value in the CD47 space, especially following significant partnerships in the field [3]. Group 4: Autoimmune and Oncology Developments - In the autoimmune sector, IMM0306 has shown promising results in treating systemic lupus erythematosus, with response rates of 71.4% and 80.0% at different dosages, demonstrating its convenience with a dosing schedule of once weekly for four weeks [4]. - In oncology, data presented at the 2025 ASH conference showed a 91.2% overall response rate (ORR) and a 67.6% complete response (CR) rate for IMM0306 in combination with lenalidomide for relapsed refractory follicular lymphoma, with plans for a Phase III trial to start in Q1 2026 [4].

Core Viewpoint - The importance of fundamental research is increasingly recognized as a key driver of national competitiveness and industrial advantages, necessitating a shift in how enterprises approach and invest in this area [4][5][6]. Group 1: Importance of Fundamental Research - Fundamental research is becoming the "first move" in industrial competition and a "source project" for national competitiveness, as international competition shifts focus to foundational theories and key mechanisms [4][8]. - The boundary between technological innovation and industrial innovation is blurring, with shorter cycles for translating fundamental breakthroughs into industrial applications [10][11]. - Enterprises are evolving into primary players in the national innovation system, with increasing capabilities in decision-making, R&D investment, and the commercialization of research outcomes [11][12]. Group 2: Changes in Enterprise Perception and Involvement - Enterprises are beginning to view fundamental research as a "core competitive asset," leading to a more systematic and internalized approach to research [14][15]. - There is a trend towards enterprises making original contributions in fundamental research, as seen in advancements like AlphaFold, which signifies a shift in the role of enterprises from merely applying science to actively shaping scientific inquiry [15][16]. - The resource allocation for fundamental research within enterprises is changing, with significant investments being made in areas like AI and biotechnology, reflecting a commitment to long-term foundational research [16][17]. Group 3: Current Challenges in Fundamental Research - Despite progress, the proportion of funding for fundamental research remains low, with only 6.9% of total R&D expenditure in China allocated to this area, compared to higher percentages in countries like the US and UK [18][19]. - Enterprises are the main executors of R&D but are underinvesting in fundamental research, with only about 1% of their R&D spending directed towards it [18][19]. - There are systemic barriers to enterprise involvement in fundamental research, including unstable expectations, risk-sharing challenges, and insufficient organizational capabilities [19][20]. Group 4: Recommendations for Enhancing Enterprise Involvement - Integrate enterprise fundamental research into national strategic tasks to create stable support and long-term arrangements [21][22]. - Develop effective incentive and risk-sharing mechanisms to encourage long-term investments in fundamental research [22][23]. - Foster collaboration between research institutions and enterprises to build a platform for innovation that addresses key industrial challenges [22][23]. - Reform talent supply and evaluation systems to support enterprises in fundamental research, emphasizing long-term contributions and original breakthroughs [23][24].

Core Viewpoint - The long-standing dispute between Kolon Biotech (科伦博泰) and its former executive team has been resolved through a settlement agreement, which includes sharing future revenues from key ADC (antibody-drug conjugate) pipelines developed by Yilian Biopharma (宜联生物) [1][2]. Group 1: Dispute Background - The dispute began in 2020 when key executives left Kolon Biotech to establish Yilian Biopharma, escalating to criminal charges and civil lawsuits regarding "trade secret infringement" by 2024-2025 [1]. - The former executives involved include Xue Tongtong, who was the General Manager at Kolon Biotech, and other key figures who played significant roles in drug development and commercialization [3]. Group 2: Settlement Details - The settlement agreement stipulates that Yilian Biopharma will share a portion of the revenues and net profits from six core ADC pipelines with Kolon Biotech, which have been developed using the TMALIN platform [1][5]. - The specific ADC pipelines mentioned include YL201, YL202, YL211, YL212, YL221, and YL222, with YL201 currently in Phase III clinical trials for small cell lung cancer and nasopharyngeal carcinoma [5]. Group 3: Financial Implications - YL202 was licensed to BioNTech for a $70 million upfront payment, with potential total payments exceeding $1 billion [5]. - YL211's global exclusive rights were granted to Roche for an upfront payment of $50 million, along with nearly $1 billion in potential milestone payments based on future sales [6]. Group 4: Strategic Insights - The settlement reflects a significant shift in Yilian Biopharma's operational strategy, which has focused on an authorization model for survival, necessitating the sharing of revenue as a cost of resolving the dispute [7].

Investment Rating - The report does not explicitly provide an investment rating for the biopharmaceutical sector [5]. Core Insights - The biopharmaceutical sector is experiencing significant activity with multiple companies focusing on innovative drug development, particularly in the area of siRNA targeting INHBE, which shows promise for fat reduction without muscle loss [3][24]. - The report highlights the recent performance of new drug stocks, with notable gains from companies such as Saint Nor Pharmaceutical (+30.88%) and Dongyao Pharmaceutical (+16.37%), while companies like Kexin Pharmaceutical (-14.19%) and Rongchang Biotechnology (-10.09%) faced declines [1][15]. - There is an expectation of multiple catalysts in the sector, including academic conferences and data releases, which could drive further interest and investment [2]. Weekly New Drug Market Review - From December 8 to December 14, 2025, the new drug sector saw significant stock movements, with the top five gainers and losers listed [1][15]. - The report notes that there were no new drug approvals during this week, but 11 new drug applications were accepted [4][31]. Weekly New Drug Industry Analysis - Wave Life Sciences has reported promising initial data for its siRNA drug WVE-007, which targets INHBE and demonstrates potential for reducing visceral fat while preserving muscle mass [3][24]. - The report indicates that several companies, both globally and domestically, are actively developing siRNA drugs targeting INHBE, with five drugs already in clinical development [27][28]. Weekly New Drug Approval & Acceptance Status - No new drug or new indication approvals were reported this week, but 11 new drug applications were accepted [4][31]. - A total of 55 new drug clinical applications were approved, and 47 new drug clinical applications were accepted during the week [9][34]. Key Events in Domestic Market - Significant events include the approval of new drugs by companies such as Zhengda Tianqing and Nuo Cheng Jian Hua, which received approval for their respective new drugs [10][11]. Key Events in Overseas Market - Noteworthy overseas events include Eli Lilly's announcement of positive results from its TRIUMPH-4 Phase 3 trial and the FDA's approval of a gene therapy by Fondazione Telethon [11].

Core Insights - Roivant is at a transformational moment with opportunities for three major product launches, each representing a pipeline-in-a-product opportunity with blockbuster potential [2] - The company is hosting an Investor Day to discuss pipeline updates and long-term value creation strategies [1][9] Program-Specific Highlights and Updates - Brepocitinib is expected to have its NDA filing for dermatomyositis in early 2026, with a commercial launch anticipated in early 2027 [6][7] - The Phase 3 trial for brepocitinib in non-infectious uveitis is fully enrolled, with topline data expected in the second half of 2026 [6][7] - A proof-of-concept trial for brepocitinib in cutaneous sarcoidosis is also fully enrolled, with topline data expected in the first half of 2026 [6][7] - IMVT-1402's potentially registrational trial in difficult-to-treat rheumatoid arthritis is expected to provide topline data in 2026 [6][7] - The ongoing Phase 2 trial of mosliciguat in pulmonary hypertension associated with interstitial lung disease is on track, with topline data expected in the second half of 2026 [5][8] Financial and Strategic Developments - Roivant's financing efforts alongside key institutional investors generated approximately $550 million for Immunovant, extending its cash runway to the launch of IMVT-1402 in Graves' disease [6][7] - The company is well-positioned to generate shareholder value through its late-stage pipeline and long-term strategy [2][6]

当地时间12月9日（周二），美国股市三大指数收盘涨跌互现。 值得注意的是，当地时间12月9日，美国零售业巨头沃尔玛从纽约证券交易所迁移至纳斯达克上市，引 发全球市场投资者的广泛关注。 商品方面，周二美盘交易时段，随着交易员在美联储利率决议前夕保持乐观情绪，贵金属集体走高，而 受到供应紧缺推动的白银则飙升至史无前例的每盎司60美元。 截至发稿，纽约期银及现货白银日内涨幅均超4%，分别至61美元/盎司及60美元/盎司上方，今年迄今， 银价已经上涨了近110%。 美股三大指数涨跌互现 航空板块整体上涨，其中美国航空、美联航均涨超1%，达美航空、西南航空涨幅均不足1%。 抗疫概念股多数下跌，吉利德科学、BioNTech、阿斯利康等多只龙头股均跌超1%；Moderna则涨近 1%。 芯片股涨跌不一，费城半导体指数跌0.04%，涨幅居前个股方面，美光科技涨超2%，拉姆研究、 ARM、博通均涨逾1%，高通涨幅不足1%；下跌芯片股方面，迈威尔科技大跌逾3%，闪迪跌逾2%，微 芯科技跌幅不足1%。 中概股多数下跌，纳斯达克中国金龙指数跌1.37%。跌幅居前的中概股方面，趣店跌逾6%，百度集团跌 超4%，贝壳、信也科技均跌近4% ...

And right now we are 2 minutes away from the end of the trading day. Romaine Bostick here alongside Katie Greifeld, taking you through to that closing bell with a global simulcast. It starts now.Carol Massar and Tim Stenovec joining us from the radio booth. Welcome to our audiences across all of our Bloomberg platforms, television, radio, as well as our partnership with YouTube. We're going to get this actually back on track here.We counted down to the closing bells with dynamism and context, because I'm to ...

Core Insights - The core viewpoint emphasizes that Biotech will remain a mainstream investment direction in the medical field, particularly focusing on the iteration of second-generation technology paradigms, such as advancements in ADC drugs and CAR-T therapies [1][2]. Group 1: Investment Trends - There is a notable phenomenon of "asset grabbing" in the market, driven by the transition of innovative drug enthusiasm from the secondary market to the primary market [1]. - As of September this year, over 40% of the innovative assets introduced by the top 20 multinational pharmaceutical companies (MNCs) in China are from local biotech firms, with half of these being next-generation therapies like dual antibodies and ADCs [2]. - Biotech companies have secured 75% of external licensing transactions, with five companies, including Hengrui Medicine and Innovent Biologics, accounting for 20% of these deals [2]. Group 2: Challenges and Opportunities - Despite the growth, the industry faces multiple challenges, including the risk of resource wastage and product homogeneity due to blind competition [3]. - The focus should shift from speed to quality improvement and differentiated innovation to avoid collective setbacks in the industry [3]. - Building a bridge between technology development and clinical needs is crucial for efficient commercialization, as demonstrated by Sequoia China's efforts in the neuroscience field [3]. Group 3: BD Transactions and Value Creation - The core value of business development (BD) transactions lies in the synergy of capital, brand, and capability, which can provide stable cash flow and enhance brand credibility for biotech companies [4]. - High-quality BD collaborations can significantly aid biotech firms in learning from leading pharmaceutical companies, thus enhancing their operational capabilities [4]. - The perception that Chinese biotech assets are undervalued in international markets needs to be addressed to improve their global competitiveness [5]. Group 4: Strategic Investment Considerations - The essence of primary market investment is to buy today and realize returns in 5 to 10 years, necessitating a focus on long-term value rather than short-term market trends [6]. - Sequoia China emphasizes the importance of selecting the right direction and team when investing, as these factors are critical for maximizing value returns [6]. - The current market environment, including the opening of the Sci-Tech Innovation Board and the surge in biotech listings in Hong Kong, provides more financing opportunities for companies, but they must ensure their fundamentals are solid before going public [6].